Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Lindis Blood Care GmbH manages a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 2 pending office actions, which are distributed across 2 distinct art units. This distribution indicates that the company's active patent applications cover diverse technical sub-sectors within the broader biotechnology field. The presence of multiple active matters suggests an ongoing investment in protecting its blood care innovations.
The prosecution involves 2 distinct examiners, providing a variety of perspectives on the pending claims. TAYLOR, LIA ELAN is the busiest examiner for the portfolio, currently responsible for 1 pending office action. This means the workload is evenly split, as the total of 2 pending office actions is shared among the 2 distinct examiners. Practitioners should note that each examiner is operating within a different art unit, requiring tailored arguments for each specific technical area. The use of 2 distinct examiners and 2 distinct art units suggests that the company's patent strategy is not centralized under a single point of review.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TAYLOR, LIA ELAN | 1 | 64.4% | +29.4% |
| YOUTCHOM PENDIE, EMMANUEL LED | 1 | 66.7% | +40.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18033942 | AN EX VIVO METHOD FOR REMOVAL OF TUMOR CELLS FROM INTRA-OPERATIVELY SALVAGED BLOOD | TAYLOR, LIA ELAN | 79d overdue |
| 17628176 | REMOVAL OF TUMOR CELLS FROM INTRAOPERATIVE AUTOLOGOUS BLOOD SALVAGE BY USING A TRIFUNCTIONAL ANTIBODY | YOUTCHOM PENDIE, EMMANUEL LED | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18033942 | AN EX VIVO METHOD FOR REMOVAL OF TUMOR CELLS FROM INTRA-OPERATIVELY SALVAGED BLOOD | TAYLOR, LIA ELAN | 1641 | §102§103DP | Final Rejection | 79d overdue | Pending | Apr 26, 2023 |
| 17628176 | REMOVAL OF TUMOR CELLS FROM INTRAOPERATIVE AUTOLOGOUS BLOOD SALVAGE BY USING A TRIFUNCTIONAL ANTIBODY | YOUTCHOM PENDIE, EMMANUEL LED | 1647 | §103DP | Final Rejection | — | Pending | Jan 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial